Apricus Biosciences, Inc. (APRI)
-NasdaqCM 2.58 
0.07(2.64%) 4:00PM EDT|After Hours
:
2.58 0.00 (0.00%) 6:04PM EDT
| Prev Close: | 2.65 |
|---|
| Open: | 2.68 |
|---|
| Bid: | 2.56 x 1000 |
|---|
| Ask: | 2.58 x 100 |
|---|
| 1y Target Est: | 5.65 |
|---|
| Beta: | 2.67 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.56 - 2.70 |
|---|
| 52wk Range: | 1.89 - 3.63 |
|---|
| Volume: | 1,547,480 |
|---|
| Avg Vol (3m): | 287,719 |
|---|
| Market Cap: | 78.80M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.23 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Apricus Bio to Float New Stock and Warrantsat Motley Fool(Fri 11:09AM EDT)
- APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri 9:23AM EDT)
- Google Saves HP’s Quarter and 3 More Hot Stocksat Wall St. Cheat Sheet(Thu, May 23)
- InPlay: Apricus Biosciences prices $17.1 mln public offering of common stock and warrants at $2.85Briefing.com(Thu, May 23)
- Apricus Biosciences Prices $17.1 Million Public Offering of Common Stock and WarrantsGlobeNewswire(Thu, May 23)
- Apricus Biosciences Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewswire(Wed, May 22)
- APRICUS BIOSCIENCES, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Eyeing Business Models and Practices that are Sustainable and Value-Creating in the Biotech and Pharmaceutical SectorsWall Street Transcript(Thu, May 16)
- APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material DEDGAR Online(Thu, May 16)
- APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other EventsEDGAR Online(Tue, May 14)
- Apricus Biosciences Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 10)
- Apricus Biosciences Provides First Quarter 2013 Corporate UpdateGlobeNewswire(Fri, May 10)
- APRICUS BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Huge Potential But Tough Entry For Female Sexual Dysfunction Drugsat Seeking Alpha(Tue, May 7)
- Apricus Biosciences Announces First Quarter 2013 Financial Results Conference CallGlobeNewswire(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 9.35 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.55 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.12 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Apricus Biosciences, Inc., a pharmaceutical company, develops and commercializes products that are primarily in the field of sexual health. It designs and develops pharmaceutical products based on its NexACT platform.
View More